ALNY director Benjamin Cravatt files initial Form 3
ALNYLAM PHARMACEUTICALS, INC. director Benjamin Cravatt has filed an initial Form 3, which is a required statement of beneficial ownership for new insiders.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ALNYLAM PHARMACEUTICALS, INC. director Benjamin Cravatt has filed an initial Form 3, which is a required statement of beneficial ownership for new insiders. This filing lists him as a director of the company but does not report any stock transactions or specific holdings in this excerpt.
Key Terms
Form 3 regulatory
reportingPersons regulatory
beneficial ownership financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the ALNY Form 3 filing by Benjamin Cravatt mean?
What role does Benjamin Cravatt have at ALNYLAM PHARMACEUTICALS, INC. (ALNY)?
Why are there no holdings or derivative positions in this ALNY Form 3 excerpt?
Does the ALNY Form 3 for Benjamin Cravatt indicate any Rule 10b5-1 trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.